

## WEST

## Freeform Search

**Database:**  US Patents Full-Text Database  US Pre-Grant Publication Full-Text Database  JPO Abstracts Database  EPO Abstracts Database  Derwent World Patents Index  IBM Technical Disclosure Bulletins

**Term:** L6 and immunoassay\$1

**Display:**  10 **Documents in Display Format:**  - **Starting with Number**  1

**Generate:**  Hit List  Hit Count  Side by Side  Image

---

---

## Search History

**DATE:** Thursday, October 10, 2002 [Printable Copy](#) [Create Case](#)

Set Name Query  
side by side

Hit Count Set Name  
result set

DB=USPT,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

<u>L8</u>	L6 and immunoassay\$1	18	<u>L8</u>
<u>L7</u>	L6 and immunoassay41	0	<u>L7</u>
<u>L6</u>	L5 and (linker or linkage)	42	<u>L6</u>
<u>L5</u>	periodate near5 (oxidase or oxidation) near5 cleav\$3	58	<u>L5</u>
<u>L4</u>	periodate near5 (oxidase or oxidation)	1610	<u>L4</u>
<u>L3</u>	periodate	7571	<u>L3</u>
<u>L2</u>	L1 and singlet oxygen	0	<u>L2</u>
<u>L1</u>	5360819.pn.	2	<u>L1</u>

END OF SEARCH HISTORY

**Search Results - Record(s) 1 through 10 of 18 returned.**

- 
- \_\_\_\_\_  1. 6344320. 07 May 99; 05 Feb 02. Electrophoresis of nascent proteins. Rothschild; Kenneth J., et al. 435/6; 435/91.1 435/91.2. C12Q001/68.

---

  - \_\_\_\_\_  2. 6306628. 25 Aug 99; 23 Oct 01. Methods for the detection, analysis and isolation of Nascent proteins. Rothschild; Kenneth J., et al. 435/91.3; 435/69.1 530/350 536/23.1 536/25.3. C12P019/34 C12P021/04 C07H021/02 C07K001/00.

---

  - \_\_\_\_\_  3. 6274343. 24 Aug 99; 14 Aug 01. Vasopermeability enhancing immunoconjugates. Epstein; Alan L., et al. 435/69.6; 424/178.1 530/382. C12P021/04 A61K039/40 A61K035/14.

---

  - \_\_\_\_\_  4. 6007817. 10 Apr 95; 28 Dec 99. Vasopermeability enhancing immunoconjugates. Epstein; Alan L., et al. 424/178.1; 424/155.1 424/174.1 424/180.1 424/183.1 435/69.6 435/70.21 530/350 530/380 530/382 530/387.1 530/388.1 530/388.8 530/388.85 530/391.1 530/391.3. A61K039/395 C12P021/04 C12N015/00 C07K001/00.

---

  - \_\_\_\_\_  5. 5851527. 19 May 95; 22 Dec 98. Method for antibody targeting of therapeutic agents. Hansen; Hans John. 424/178.1; 424/179.1 424/181.1 424/9.1 530/391.1. A61K039/395.

---

  - \_\_\_\_\_  6. 5808021. 10 Apr 97; 15 Sep 98. Method for controlling O-desulfation of heparin. Holme; Kevin R., et al. 536/21;. A61K031/725 C08B037/10.

---

  - \_\_\_\_\_  7. 5795875. 09 Jan 97; 18 Aug 98. Therapeutic methods of using O-desulfated heparin derivatives. Holme; Kevin R., et al. 514/56; 514/921 536/21. A61K031/725 C08B037/10.

---

  - \_\_\_\_\_  8. 5707877. 23 Jun 95; 13 Jan 98. Biodegradable gelatin-aminodextran particle coatings of and processes for making same. Siiman; Olavi, et al. 436/518; 436/528 436/529 536/112 536/51. G01N033/543.

---

  - \_\_\_\_\_  9. 5696100. 06 Feb 95; 09 Dec 97. Method for controlling O-desulfation of heparin and compositions produced thereby. Holme; Kevin R., et al. 514/56; 514/54 536/21. A61K031/725.

---

  - \_\_\_\_\_  10. 5641539. 01 Jun 95; 24 Jun 97. Molecular imaging. Afeyan; Noubar B., et al. 427/222; 210/502.1 210/638. B01D015/08.
-

[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 18 of 18 returned.**

- 
11. 5583112. 02 Jul 92; 10 Dec 96. Saponin-antigen conjugates and the use thereof. Kensiil; Charlotte A., et al. 514/25; 424/184.1 424/194.1 424/197.11 424/278.1 514/23 514/26 514/53 514/54 514/61 530/395 536/4.1 536/5 536/6 536/6.1. A61K031/115 A61K031/70 A61K031/705 A61K039/10.
- 
12. 5466609. 29 Oct 92; 14 Nov 95. Biodegradable gelatin-aminodextran particle coatings of and processes for making same. Siiman; Olavi, et al. 436/518; 427/127 427/2.11 427/2.13 427/2.14 427/212 427/213.31 427/213.33 427/214 427/216 427/337 427/402 427/414 428/403 436/524 436/525 436/526 436/528 436/529 436/532 436/534 530/391.1 530/810 530/812 530/813. G01N033/531 G01N033/543 G01N033/548.
- 
13. 5453199. 20 May 94; 26 Sep 95. Molecular imaging. Afeyan; Noubar B., et al. 210/638; 210/502.1. B01D015/08.
- 
14. 5372719. 30 Mar 92; 13 Dec 94. Molecular imaging. Afeyan; Noubar B., et al. 210/502.1; 210/638 210/656. B01D015/08.
- 
15. 5296471. 22 Dec 92; 22 Mar 94. Method for controlling o-desulfation of heparin and compositions produced thereby. Holme; Kevin R., et al. 514/56; 514/54 536/21. A61K031/725 C08R037/10.
- 
16. 5061790. 10 Jul 89; 29 Oct 91. Oxidative denaturation of protein analytes. Elting; James J., et al. 530/402; 530/403 530/404 530/405 530/406 530/408 530/409 530/410. C07K003/00 C07K013/00 C07K015/00 C07K017/00.
- 
17. 4948836. 14 Nov 88; 14 Aug 90. Immobilized antibodies. Solomon; Beka, et al. 525/54.1; 436/531 436/532 530/815 530/816. C08H001/00 C08L089/00 A61K035/14.
- 
18. 4831126. 26 Feb 85; 16 May 89. Antigenic polysaccharide specific to Brucella abortus and Yersinia enterocolitica serotype 0:9. Bundle; David R., et al. 536/53; 435/101 435/7.32 435/822 530/388.4 536/123.1 536/18.7 536/55.1. C08B037/00 C07H005/04 C12P019/04 A61K039/02.
- 

[Generate Collection](#)[Print](#)

Generate Collection

L10: Entry 1 of 9

File: USPT

May 1, 2001

DOCUMENT-IDENTIFIER: US 6224903 B1

TITLE: Polymer-lipid conjugate for fusion of target membranes

Detailed Description Text (59):

Such chemical linkages include those which can be cleaved under selective physiological conditions, such as in the presence of enzymes or reducing agents. For example, ester or peptide linkages are cleaved by hydrolytic enzymes, such as esterases or peptidases, and disulfide linkages are cleaved by reducing agents such as glutathione, cysteine, or ascorbate normally present in plasma and intracellularly, or these same agents introduced into plasma by, for example, injection. Other releasable linkages include pH sensitive bonds and bonds which are cleaved upon exposure to light or heat.

Detailed Description Text (142):

The fusogenic liposome composition may be targeted to a cell or a target liposome in vitro for use in a homogenous immunoassay format.

**Search Results - Record(s) 1 through 9 of 9 returned.**

1. 6224903. 10 Dec 98; 01 May 01. Polymer-lipid conjugate for fusion of target membranes. Martin; Francis J., et al. 424/450; 554/101 554/35 554/79 554/85. A61K009/127.
2. 6217869. 05 Sep 97; 17 Apr 01. Pretargeting methods and compounds. Meyer; Damon L., et al. 424/178.1; 424/1.53 424/179.1 530/367 530/391.1 530/391.3 530/391.5 530/402. A61K039/00 C07K001/107 C07K016/46.
3. 6015897. 13 May 96; 18 Jan 00. Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota. Theodore; Louis J., et al. 540/474;. C07D257/02.
4. 5891468. 10 Oct 97; 06 Apr 99. Fusogenic liposome compositions and method. Martin; Francis J., et al. 424/450; 436/829. A61K009/127.
5. 4791055. 09 Jan 86; 13 Dec 88. Homogenous specific binding assay reagent system and labeled conjugates. Boguslaski; Robert C., et al. 435/7.7; 435/174 435/7.72 435/7.91 436/537 436/544 436/546. G01N033/532 G01N033/533 G01N033/542 C12N011/16.
6. 4629688. 10 Apr 78; 16 Dec 86. Homogeneous specific binding assay method. Bolguslaski; Robert C., et al. 435/7.7; 435/174 435/7.5 435/7.71 435/7.72 435/966 436/537 436/544 436/546. G01N033/54 G01N033/58 C12N011/00.
7. 4399099. 14 Sep 81; 16 Aug 83. Optical fiber apparatus for quantitative analysis. Buckles; Richard G.. 422/58; 356/445 422/60 422/82.11 435/7.1 435/968 436/136 436/138 436/165 436/514 436/527 436/535 436/537 436/805 436/807. G01N021/64.
8. 4383031. 21 Jun 79; 10 May 83. Homogeneous chemiluminescent specific binding assay. Boguslaski; Robert C., et al. 435/7.72; 422/61 435/7.5 435/7.7 435/7.91 435/7.93 435/968 435/971 436/536 436/805 436/808 436/817. G01N033/54 G01N033/58 G01N021/76.
9. 4321057. 20 Sep 79; 23 Mar 82. Method for quantitative analysis using optical fibers. Buckles; Richard G.. 435/7.1; 356/445 422/58 422/60 422/82.01 422/82.08 435/14 435/4 435/7.92 436/151 436/172 436/537 436/543 436/57 436/68 436/800 436/805 436/95. G01N021/64.